UY28407A1 - Agentes terapeuticos - Google Patents

Agentes terapeuticos

Info

Publication number
UY28407A1
UY28407A1 UY28407A UY28407A UY28407A1 UY 28407 A1 UY28407 A1 UY 28407A1 UY 28407 A UY28407 A UY 28407A UY 28407 A UY28407 A UY 28407A UY 28407 A1 UY28407 A1 UY 28407A1
Authority
UY
Uruguay
Prior art keywords
linked
compounds
therapeutic agents
cynical
nr1h2
Prior art date
Application number
UY28407A
Other languages
English (en)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28407A1 publication Critical patent/UY28407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a ciertos compuestos novedosos de fórmula I: a procedimientos para la preparación de dichos compuesots, a su utilización en la modulación de los receptores de hormonas nucleares tales como el Receptor Hepático X (LXR), a (NR1H3) y/o b (NR1H2) y en el tratamiento y/o prevención de condiciones cínicas inclusive enfermedades cardiovasculares tales como la ateroesclerosis, enfermedades inflamatorias, mal del Alzheimer, trastornos lipídicos (dislipidemias) vinculados o no vinculados a la resistencia a la insulina, diabetes tipo 2 y otras manifestaciones del síndrome metabólico, a métodos para su uso terapéutico y a composiciones farmacéuticas que los contienen.
UY28407A 2003-07-11 2004-07-09 Agentes terapeuticos UY28407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
UY28407A1 true UY28407A1 (es) 2005-02-28

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28407A UY28407A1 (es) 2003-07-11 2004-07-09 Agentes terapeuticos

Country Status (26)

Country Link
US (1) US20060189663A1 (es)
EP (1) EP1646625B1 (es)
JP (1) JP2007521313A (es)
KR (1) KR20060034284A (es)
CN (1) CN100478340C (es)
AR (1) AR045720A1 (es)
AT (1) ATE399776T1 (es)
AU (1) AU2004256000B2 (es)
BR (1) BRPI0412479A (es)
CA (1) CA2532068A1 (es)
CO (1) CO5640134A2 (es)
DE (1) DE602004014772D1 (es)
ES (1) ES2308205T3 (es)
GB (1) GB0316237D0 (es)
HK (1) HK1088318A1 (es)
IL (1) IL172759A0 (es)
IS (1) IS8291A (es)
MX (1) MXPA06000447A (es)
NO (1) NO20060080L (es)
RU (1) RU2006102129A (es)
SA (1) SA04250203B1 (es)
TW (1) TW200507836A (es)
UA (1) UA82108C2 (es)
UY (1) UY28407A1 (es)
WO (1) WO2005005416A1 (es)
ZA (1) ZA200600229B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526841A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
US7989179B2 (en) * 2005-06-28 2011-08-02 Daiichi Sankyo Company, Limited LXR ligand testing method
WO2008024724A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100056444A1 (en) 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
SI2868315T1 (sl) 2007-12-04 2017-10-30 Biogen Chesapeake Llc Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
KR20110028376A (ko) 2008-07-01 2011-03-17 제넨테크, 인크. Ｍｅｋ 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels

Also Published As

Publication number Publication date
NO20060080L (no) 2006-02-08
CN1820003A (zh) 2006-08-16
IS8291A (is) 2006-02-09
ES2308205T3 (es) 2008-12-01
EP1646625B1 (en) 2008-07-02
GB0316237D0 (en) 2003-08-13
HK1088318A1 (en) 2006-11-03
KR20060034284A (ko) 2006-04-21
SA04250203B1 (ar) 2008-02-25
AR045720A1 (es) 2005-11-09
RU2006102129A (ru) 2006-08-27
BRPI0412479A (pt) 2006-09-19
AU2004256000A1 (en) 2005-01-20
AU2004256000B2 (en) 2007-07-26
ZA200600229B (en) 2007-04-25
ATE399776T1 (de) 2008-07-15
CA2532068A1 (en) 2005-01-20
MXPA06000447A (es) 2006-04-07
TW200507836A (en) 2005-03-01
CO5640134A2 (es) 2006-05-31
US20060189663A1 (en) 2006-08-24
UA82108C2 (uk) 2008-03-11
EP1646625A1 (en) 2006-04-19
DE602004014772D1 (de) 2008-08-14
WO2005005416A1 (en) 2005-01-20
IL172759A0 (en) 2006-04-10
CN100478340C (zh) 2009-04-15
JP2007521313A (ja) 2007-08-02

Similar Documents

Publication Publication Date Title
UY28407A1 (es) Agentes terapeuticos
UY28408A1 (es) Agentes terapeuticos
BRPI0606391A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
UY28752A1 (es) Agentes terapeuticos
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
PA8564001A1 (es) Aza-arilpiperazinas
BRPI0717023B8 (pt) tiazol pirazolopirimidina, seu uso, e composição farmacêutica
BRPI0606388A2 (pt) composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
SE0500056D0 (sv) Therapeutic agents 4
UY28839A1 (es) Agentes terapeuticos
SE0500058D0 (sv) Therapeutic agents 5
UY28377A1 (es) Agentes terapeuticos
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
CL2004000779A1 (es) Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en
UY29635A1 (es) Derivados anilinicos de 1,1-dioxidos de isotiazol-3(2h)-ona como moduladores del receptor hepatico x
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
SE0500054D0 (sv) Therapeutic agents 2
UY29634A1 (es) Derivados no anilinicos de 1,1-dioxidos de isotiazol-3(2h)-ona como moduladores de los receptores hepaticos x
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
UY28370A1 (es) Agentes terapéuticos
MY143584A (en) Non-anilinic derivatives of isothiazol-3(2h)-one 1, 1-dioxides as liver x receptor modulators
TH79980B (th) อนุพันธ์แอนิลินิคของไอโซไธอะซอล-3(2h)-โอน 1,1-ไดออกไซด์ ในฐานะเป็นตัวควบคุมตัวรับ x ของตับ

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120613